This content is machine translated ASH Congress in New Orleans What were the highlights? At the end of 2013, the 55th annual congress of the “American Society of Hematology” took place. Over 22,000 participants came to New Orleans, or “The Big Easy” as the…
View Post 4 min This content is machine translated Non-Hodgkin's Lymphoma Bortezomib in previously untreated multiple myeloma. A subanalysis of the VISTA trial was presented at the ASH Congress in New Orleans, showing that a higher cumulative dose of bortezomib resulted in a better outcome in patients…
View Post 3 min This content is machine translated Non-Hodgkin's Lymphoma Pomalidomide in high-risk patients. Because data on the efficacy of pomalidomide in high-risk relapsed/refractory multiple myeloma populations are sparse, a phase II study set out to evaluate the agent in patients with GEP70 or…
View Post 3 min This content is machine translated Follicular lymphoma Rituximab in maintenance monotherapy. A study presented at ASH 2013 in New Orleans examined the role of rituximab in maintenance therapy in patients with follicular lymphoma. The study showed that the drug, when applied…
View Post 2 min This content is machine translated Multiple Myeloma Media Workshop Which form of therapy is suitable for whom? At a media workshop during the ASH Congress in New Orleans, some key points of myeloma research were presented. They also discussed what these innovations mean for patients and used…
View Post 6 min This content is machine translated Non-Hodgkin's lymphoma and myelodysplastic syndrome What are the benefits of lenalidomide and pomalidomide? At the ASH Congress in New Orleans, the focus was on the efficacy and safety of lenalidomide plus low-dose dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.…
